登录 注册 会员服务 联系我们

Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

  • Published:2014-10 Issue:10 Volume:41 Page:788-797
  • ISSN:0305-1870
  • Container-title:Clinical and Experimental Pharmacology and Physiology
  • language:en
  • Short-container-title:Clin Exp Pharmacol Physiol

Author:

Shiha Gamal E1,Abu-Elsaad Nashwa M2,Zalata Khaled R3,Ibrahim Tarek M2

Affiliation:

1. Departments of Internal Medicine; Mansoura University; Mansoura Egypt

2. Department of Pathology; Faculty of Medicine; Mansoura University; Mansoura Egypt

3. Department of Pharmacology and Toxicology; Faculty of Pharmacy; Mansoura University; Mansoura Egypt

Funder

Science and Technology Development Fund

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Reference51 articles.

1. Role of tyrosine kinase inhibitors in cancer therapy;Arora;J. Pharmacol. Exp. Ther.,2005

2. Therapeutic protein kinase inhibitors;Grant;Cell. Mol. Life Sci.,2009

3. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?;Beyer;Swiss Med. Wkly.,2010

4. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis;Distler;Rheumatology,2008

5. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo;Wang;FASEB J.,2005
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3